08:15 AM EDT, 09/24/2025 (MT Newswires) -- Predictmedix AI ( PMEDF ) said Wednesday it is developing an adaptive-AI engine to simulate, and predict outcomes across multi-site clinical trials. The SaaS-based platform is intended to provide trial simulation, cross-trial learning, cost/outcome modeling, and full regulatory traceability.

According to a statement, the global clinical trials market is projected to reach $123.5 billion by 2030, growing at a compound annual growth rate of nearly 6.5 % from 2024 to 2030.

The company is also planning to undertake global commercialization of its Smart AI stations. The stations' contactless, screening systems have demonstrated 95% accuracy in detecting impairment, and infectious disease for example, supported by independent, multi-center clinical validation. Predictmedix is assessing regulatory requirements in multiple jurisdictions, including Southeast Asia, and plans to initiate formal medical-device certification processes as a next step toward global deployment.

A planned mobile application will also use Predictmedix's imaging technology to deliver vital-sign monitoring through a smartphone, extending its reach into the digital-health and telehealth markets.

"Our validated SmartHealth technology provides the data, AI engine, and market credibility to scale across enterprise, clinical-research, and consumer segments," said Dr. Rahul Kushwah, chief operating officer. "This multi-vertical approach is designed to diversify revenue and support sustainable long-term growth for our shareholders."